First-line phase II trial of sorafenib (BAY 43–9006) in patients with advanced renal cell carcinoma unsuitable for cytokine treatment No significant financial relationships to disclose. This is an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results